← Leaderboards
Steven J Gray
Univ Of North Carolina Chapel Hill
$7,162,149
Attributed
$8,707,346
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,502,602 · 5
By mechanism
U19$14,724,998 · 2
R01$4,628,215 · 2
U01$2,149,389 · 1
Top collaborators
- Mandana Arbab3 shared
- David R Liu3 shared
- Cathleen M Lutz3 shared
- Ricardo Mouro Pinto3 shared
- Berge A Minassian2 shared
- Diane Armao1 shared
- Susan T Iannaccone1 shared
- Thomas J. Mccown1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Neeta L Vora$4,466,052
- Thomas J. McCown$7,445,525
- Kenneth N. Olivier$1,352,643
- Alexandra Freeman$275,617
- Adam Shapiro$275,617
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesNervous System DisorderGene TherapyDoseVectorClinical TrialsInvestigational DrugsNeuronsCerebrospinal FluidTranslatingTranslationsSpinal Muscular AtrophyBiodistributionChildhoodPreclinical StudyTissuesLifeMeetingsSafetyAstrocytesBrainPeripheralOrganGene Transfer
Grant awards (20)
Preclinical Genome Editing for Rare Neurological Diseases$4,319,346
U19 · FY2025 · NS
IND-enabling studies for Aspartylglucosaminuria (AGU) to support the initiation of an AAV9/AGA gene transfer clinical trial$744,158
U01 · FY2025 · NS · contact PI
Viral Vector and Regulatory Core$716,846
U19 · FY2025 · NS · contact PI
Preclinical Genome Editing for Rare Neurological Diseases$4,213,908
U19 · FY2024 · NS
IND-enabling studies for Aspartylglucosaminuria (AGU) to support the initiation of an AAV9/AGA gene transfer clinical trial$773,534
U01 · FY2024 · NS · contact PI
Viral Vector and Regulatory Core$603,025
U19 · FY2024 · NS · contact PI
Preclinical Genome Editing for Rare Neurological Diseases$4,262,002
U19 · FY2023 · NS
IND-enabling studies for Aspartylglucosaminuria (AGU) to support the initiation of an AAV9/AGA gene transfer clinical trial$631,697
U01 · FY2023 · NS · contact PI
Viral Vector and Regulatory Core$609,871
U19 · FY2023 · NS · contact PI
Directed Evolution of Novel AAV Capsis for Global CNS Delivery in Rodents and Primates$514,303
R01 · FY2021 · NS · contact PI
Directed Evolution of Novel AAV Capsis for Global CNS Delivery in Rodents and Primates$570,525
R01 · FY2020 · NS · contact PI
Directed Evolution of Novel AAV Capsis for Global CNS Delivery in Rodents and Primates$581,447
R01 · FY2018 · NS · contact PI
Giant Axonal Neuropathy Gene Therapy$354,375
R01 · FY2018 · NS · contact PI
Directed Evolution of Novel AAV Capsids for Global CNS Delivery in Rodents and Primates$586,631
R01 · FY2017 · NS · contact PI
Giant Axonal Neuropathy Gene Therapy$328,860
R01 · FY2017 · NS · contact PI
Giant Axonal Neuropathy Gene Therapy$45,271
R01 · FY2017 · NS · contact PI
Directed Evolution of Novel AAV Capsids for Global CNS Delivery in Rodents and Primates$668,413
R01 · FY2016 · NS · contact PI
Giant Axonal Neuropathy Gene Therapy$327,040
R01 · FY2016 · NS · contact PI
Giant Axonal Neuropathy Gene Therapy$325,675
R01 · FY2015 · NS · contact PI
Giant Axonal Neuropathy Gene Therapy$325,675
R01 · FY2014 · NS · contact PI